BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gschwend S, Ebert W, Schultze-Mosgau M, Breuer J. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment. Invest Radiol. 2011;46:556-566. [PMID: 21623212 DOI: 10.1097/rli.0b013e31821a218a] [Cited by in Crossref: 69] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 Forsgren MF, Dahlqvist Leinhard O, Dahlström N, Cedersund G, Lundberg P. Physiologically realistic and validated mathematical liver model reveals [corrected] hepatobiliary transfer rates for Gd-EOB-DTPA using human DCE-MRI data. PLoS One 2014;9:e95700. [PMID: 24748411 DOI: 10.1371/journal.pone.0095700] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
2 Rimola J, Forner A. Hepatobiliary contrast agents in MR: Where we stand and future perspectives. Liver Int 2021;41:888-90. [PMID: 33861894 DOI: 10.1111/liv.14883] [Reference Citation Analysis]
3 D'Ippolito G. The role of MRI using liver-specific contrast agent in the assessment of focal liver lesion. Radiol Bras 2014;47:VII-VIII. [PMID: 25741113 DOI: 10.1590/0100-3984.2014.47.5e2] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
4 Geisel D, Raabe P, Lüdemann L, Malinowski M, Stockmann M, Seehofer D, Pratschke J, Hamm B, Denecke T. Gd-EOB-DTPA-enhanced MRI for monitoring future liver remnant function after portal vein embolization and extended hemihepatectomy: A prospective trial. Eur Radiol 2017;27:3080-7. [DOI: 10.1007/s00330-016-4674-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
5 Endrikat J, Schwenke C, Vogtlaender K, Dohannish S, Breuer J. Safety profile of gadoxetate disodium in elderly patients (≥65 years). Acta Radiol 2018;59:81-8. [PMID: 28372493 DOI: 10.1177/0284185117700673] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
6 Mar WA, Chan HK, Trivedi SB, Berggruen SM. Imaging of Intrahepatic Cholangiocarcinoma. Semin Ultrasound CT MR 2021;42:366-80. [PMID: 34130849 DOI: 10.1053/j.sult.2021.04.001] [Reference Citation Analysis]
7 Lauenstein T, Ramirez-Garrido F, Kim YH, Rha SE, Ricke J, Phongkitkarun S, Boettcher J, Gupta RT, Korpraphong P, Tanomkiat W, Furtner J, Liu PS, Henry M, Endrikat J. Nephrogenic systemic fibrosis risk after liver magnetic resonance imaging with gadoxetate disodium in patients with moderate to severe renal impairment: results of a prospective, open-label, multicenter study. Invest Radiol 2015;50:416-22. [PMID: 25756684 DOI: 10.1097/RLI.0000000000000145] [Cited by in Crossref: 39] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
8 Gotra A, Sivakumaran L, Chartrand G, Vu KN, Vandenbroucke-Menu F, Kauffmann C, Kadoury S, Gallix B, de Guise JA, Tang A. Liver segmentation: indications, techniques and future directions. Insights Imaging 2017;8:377-92. [PMID: 28616760 DOI: 10.1007/s13244-017-0558-1] [Cited by in Crossref: 51] [Cited by in F6Publishing: 33] [Article Influence: 10.2] [Reference Citation Analysis]
9 Han D, Liu J, Jin E, He W. Liver assessment using Gd-EOB-DTPA-enhanced magnetic resonance imaging in primary biliary cholangitis patients. Jpn J Radiol 2019;37:412-9. [PMID: 30798469 DOI: 10.1007/s11604-019-00822-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
10 Tseng TY, Tseng JH, Huang BS, Lin SY, Chen CB, Fang YW, Lin G, Lai YC. Risk of nephrogenic systemic fibrosis in patients with impaired renal function undergoing fixed-dose gadoxetic acid-enhanced magnetic resonance imaging. Abdom Radiol (NY) 2021;46:3995-4001. [PMID: 33742216 DOI: 10.1007/s00261-021-03045-4] [Reference Citation Analysis]
11 Wang X, Wang Y, Zhang Z, Zhou M, Zhou X, Zhao H, Xing J, Zhou Y. Rim enhancement on hepatobiliary phase of pre-treatment 3.0 T MRI: A potential marker for early chemotherapy response in colorectal liver metastases treated with XELOX. Eur J Radiol 2021;143:109887. [PMID: 34454297 DOI: 10.1016/j.ejrad.2021.109887] [Reference Citation Analysis]
12 Rassam F, Zhang T, Cieslak KP, Lavini C, Stoker J, Bennink RJ, van Gulik TM, van Vliet LJ, Runge JH, Vos FM. Comparison between dynamic gadoxetate-enhanced MRI and 99mTc-mebrofenin hepatobiliary scintigraphy with SPECT for quantitative assessment of liver function. Eur Radiol 2019;29:5063-72. [PMID: 30796575 DOI: 10.1007/s00330-019-06029-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
13 Endrikat J, Kim SY, Sakaguchi T, Dohanish S, Breuer J. Safety of gadoxetate disodium: results from six clinical phase IV studies in 8194 patients. Acta Radiol 2016;57:1326-33. [PMID: 26048848 DOI: 10.1177/0284185115588126] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
14 Geller J, Kasahara M, Martinez M, Soresina A, Kashanian F, Endrikat J. Safety and Efficacy of Gadoxetate Disodium-Enhanced Liver MRI in Pediatric Patients Aged >2 Months to <18 Years-Results of a Retrospective, Multicenter Study. Magn Reson Insights 2016;9:21-8. [PMID: 27478381 DOI: 10.4137/MRI.S39091] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
15 Erstad DJ, Ramsay IA, Jordan VC, Sojoodi M, Fuchs BC, Tanabe KK, Caravan P, Gale EM. Tumor Contrast Enhancement and Whole-Body Elimination of the Manganese-Based Magnetic Resonance Imaging Contrast Agent Mn-PyC3A. Invest Radiol 2019;54:697-703. [PMID: 31356382 DOI: 10.1097/RLI.0000000000000593] [Cited by in Crossref: 20] [Cited by in F6Publishing: 4] [Article Influence: 10.0] [Reference Citation Analysis]
16 Matoori S, Froehlich JM, Breitenstein S, Doert A, Pozdniakova V, Koh DM, Gutzeit A. Age dependence of spleen- and muscle-corrected hepatic signal enhancement on hepatobiliary phase gadoxetate MRI. Eur Radiol 2016;26:1889-94. [PMID: 26334505 DOI: 10.1007/s00330-015-3965-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
17 Yeom SK, Lee SW, Cha SH, Chung HH, Je BK, Kim BH, Hyun JJ. Biliary reflux detection in anomalous union of the pancreatico-biliary duct patients. World J Gastroenterol 2012; 18(9): 952-959 [PMID: 22408355 DOI: 10.3748/wjg.v18.i9.952] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
18 Tanabe M, Tanabe M, Furukawa M, Iida E, Okada M, Ito K. Assessment of the relationship between the hepatic contrast enhancement effect in the hepatobiliary phase and hepatic signal changes in free-breathing continuous multiphasic dynamic EOB-MRI. Eur J Radiol 2021;144:109959. [PMID: 34583170 DOI: 10.1016/j.ejrad.2021.109959] [Reference Citation Analysis]
19 Kirchin MA, Lorusso V, Pirovano G. Compensatory biliary and urinary excretion of gadobenate ion after administration of gadobenate dimeglumine (MultiHance(®)) in cases of impaired hepatic or renal function: a mechanism that may aid in the prevention of nephrogenic systemic fibrosis? Br J Radiol 2015;88:20140526. [PMID: 25651409 DOI: 10.1259/bjr.20140526] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
20 Francisco FA, de Araújo AL, Oliveira Neto JA, Parente DB. Hepatobiliary contrast agents: differential diagnosis of focal hepatic lesions, pitfalls and other indications. Radiol Bras 2014;47:301-9. [PMID: 25741105 DOI: 10.1590/0100-3984.2013.1867] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
21 Geisel D, Lüdemann L, Fröling V, Malinowski M, Stockmann M, Baron A, Gebauer B, Seehofer D, Prasad V, Denecke T. Imaging-based evaluation of liver function: comparison of 99mTc-mebrofenin hepatobiliary scintigraphy and Gd-EOB-DTPA-enhanced MRI. Eur Radiol. 2015;25:1384-1391. [PMID: 25447973 DOI: 10.1007/s00330-014-3536-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]